GlassScriptPhysician profile
Kaitlin C Schild
NPI 1356889182
$3,616.51
in general payments reported to CMS, 2019-2025
19 companies · $562 in 2025
The $562 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $529 · 2023: $1,205 · 2024: $863 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.30 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.30 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $559.57 | 2022-2023 | |
| Janssen Biotech, INC. | $448.07 | 2021-2025 | Tremfya, Stelara |
| Genzyme Corporation | $375.36 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $252.86 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $177.82 | 2023-2024 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.30 | 2021-2023 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $138.09 | 2021 | |
| Braintree Laboratories, INC. | $137.21 | 2021 | |
| Ironwood Pharmaceuticals, INC | $113.53 | 2023-2024 | Linzess |
| Ardelyx, INC. | $108.53 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $91.31 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $52.63 | 2024 | Dupixent |
| Daiichi Sankyo INC. | $45.17 | 2022-2023 | Injectafer |
| Celgene Corporation | $31.78 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.97 | 2024 | Omvoh |
| Amgen INC. | $18.74 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $14.47 | 2023 | Movantik, Aemcolo, Talicia |
| Celltrion USA INC. | $13.80 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Schild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.